gIcare Pharma initiates Phase 2a study of its lead product, GIC-1001, in sedation-free analgesia for colorectal cancer screening

gIcare Pharma Inc today announced the initiation of a phase 2a study ofGIC-1001, a novel orally-administered opioid agonist drug candidate to providesedation-free, colonic analgesia in patients undergoing colonoscopy.